Ringdén O, Labopin M, Bacigalupo A, Arcese W, Schaefer U W, Willemze R, Koc H, Bunjes D, Gluckman E, Rocha V, Schattenberg A, Frassoni F
Centre for Allogeneic Stem Cell Transplantation, Huddinge, Sweden.
J Clin Oncol. 2002 Dec 15;20(24):4655-64. doi: 10.1200/JCO.2002.12.049.
Several studies show that allogeneic peripheral blood stem cells (PBSCs) engraft more rapidly than bone marrow (BM). However, the data are inconsistent with regard to acute and chronic graft-versus-host disease (GVHD), relapse, transplant-related mortality (TRM), and leukemia-free survival (LFS).
Between January 1994 and December 2000, 3,465 adult patients (older than 15 years of age) were reported to the European Group for Blood and Marrow Transplantation Registry from 224 centers. Among acute myeloid leukemia (AML) patients, 1,537 patients received BM and 757 patients received PBSC. In acute lymphoblastic leukemia (ALL) patients, the corresponding figures were 826 versus 345 patients who were analyzed for engraftment, GVHD, TRM, relapse, LFS, and survival.
In multivariate analysis, the recovery of neutrophils and platelets was faster with PBSC than with BM (P <.0001). Chronic GVHD was associated with PBSC in patients with AML (relative risk [RR], 2.11; 95% confidence interval, 1.66 to 2.7; P <.0001) and ALL (RR, 1.56; 95% confidence interval, 1.09 to 2.27; P =.02). PBSC versus BM in patients with AML or ALL was not significantly associated with acute GVHD, TRM, relapse, survival, or LFS. In multivariate analysis of patients with AML, factors significantly associated with improved LFS included first remission at transplant (P <.0001), promyelocytic leukemia (M3) versus other French-American-British types (P <.0001), and donor age below median 37 years (P =.02). In patients with ALL, first remission (P <.0001) and methotrexate included in the immunosuppressive regimen (P =.001) were associated with improved LFS.
Allogeneic PBSC results in faster neutrophil and platelet engraftment and a higher incidence of chronic GVHD than BM. However, acute GVHD, TRM, relapse, survival, and LFS were similar in patients receiving PBSCs versus BM.
多项研究表明,异基因外周血干细胞(PBSC)的植入速度比骨髓(BM)更快。然而,关于急性和慢性移植物抗宿主病(GVHD)、复发、移植相关死亡率(TRM)和无白血病生存期(LFS)的数据并不一致。
1994年1月至2000年12月期间,224个中心向欧洲血液和骨髓移植登记处报告了3465例成年患者(年龄超过15岁)。在急性髓系白血病(AML)患者中,1537例接受了BM移植,757例接受了PBSC移植。在急性淋巴细胞白血病(ALL)患者中,相应的数据分别为826例和345例,对这些患者进行了植入、GVHD、TRM、复发、LFS和生存情况的分析。
在多变量分析中,PBSC组中性粒细胞和血小板的恢复速度比BM组更快(P <.0001)。AML患者中慢性GVHD与PBSC相关(相对风险[RR],2.11;95%置信区间,1.66至2.7;P <.0001),ALL患者中也是如此(RR,1.56;95%置信区间,1.09至2.27;P =.02)。AML或ALL患者中,PBSC与BM相比,与急性GVHD、TRM、复发、生存或LFS无显著相关性。在AML患者的多变量分析中,与改善LFS显著相关的因素包括移植时处于首次缓解期(P <.0001)、早幼粒细胞白血病(M3)与其他法美英分型(P <.0001)以及供体年龄低于中位数37岁(P =.02)。在ALL患者中,首次缓解期(P <.0001)和免疫抑制方案中包含甲氨蝶呤(P =.001)与改善LFS相关。
异基因PBSC导致中性粒细胞和血小板植入更快,且慢性GVHD的发生率高于BM。然而,接受PBSC与BM的患者在急性GVHD、TRM、复发、生存和LFS方面相似。